Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 3 · 37.5%Very low 2 · 25%Low 0 · 0%Moderate 3 · 37.5%High 0 · 0%

Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone

Major bleeding · people requiring treatment for acute DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 500 participants
Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Major bleeding · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.98 [0.29, 3.34]
1 study · 583 participants
Moderate

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone

Major bleeding · people requiring treatment for chronic DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 224 participants
Very low

Anticoagulant vs antiplatelet agent

Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Moderate

Anticoagulant with or without ASA vs ASA only

Major bleeding · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 493 participants
GRADE not reported

Aspirin vs placebo

Major bleeding · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
GRADE not reported

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

Bleeding ‐ major/excessive · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
GRADE not reported

ASA with LMWH vs placebo or IVIG

Bleeding ‐ major (bleeding requiring transfusion) Length of · people with antiphospholipid antibodies and no history of thrombosis

ASA with LMWH showed no clear difference in bleeding ‐ major (bleeding requiring transfusion) Length of compared with placebo or IVIG (moderate certainty).

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
RR 9 [0.49, 164.76]
1 study · 180 participants
Moderate